Loading stock data…
$10.19-0.35 (-3.32%)
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases.
Climb Bio, Inc. in the Healthcare sector is trading at $10.19 with a market capitalization of $818M. Wall Street consensus targets $27.60 (15 analysts), implying a +170.9% move over the next 12 months. The stock is currently 44% below its 52-week high of $18.33, remaining 0.6% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.36M↓ | -$15.21M↑ | -$19.30M↓ | -$14.89M↓ | -$10.68M |
| Net Income | -$13.50M↑ | -$13.72M↑ | -$17.52M↓ | -$12.89M↓ | -$8.67M |
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibod...